Last reviewed · How we verify
LNG-EE
LNG-EE is a combined oral contraceptive containing levonorgestrel (a progestin) and ethinyl estradiol (an estrogen) that prevents pregnancy by suppressing ovulation and altering cervical mucus.
LNG-EE is a combined oral contraceptive containing levonorgestrel (a progestin) and ethinyl estradiol (an estrogen) that prevents pregnancy by suppressing ovulation and altering cervical mucus. Used for Contraception / prevention of pregnancy, Regulation of menstrual cycles.
At a glance
| Generic name | LNG-EE |
|---|---|
| Also known as | SCH 900121 |
| Sponsor | Organon and Co |
| Drug class | Combined oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | Phase 3 |
Mechanism of action
The progestin component inhibits the luteinizing hormone (LH) surge necessary for ovulation, while the estrogen suppresses follicle-stimulating hormone (FSH) to prevent follicle development. Together, these hormones also thicken cervical mucus to impede sperm penetration and alter the endometrium to reduce implantation likelihood.
Approved indications
- Contraception / prevention of pregnancy
- Regulation of menstrual cycles
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (PHASE1)
- Role of Estrogen on Skeletal Outcomes in FHA (PHASE2)
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (PHASE1)
- A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age (PHASE1)
- International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
- International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study
- Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNG-EE CI brief — competitive landscape report
- LNG-EE updates RSS · CI watch RSS
- Organon and Co portfolio CI